Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Aron Ceccarelli
Period: Reporting periods mapped to calendar 2024 Q4 – 2025 Q2 (3 quarters).
- Questions
- 7on tracked calls
- Challenge rate
- 14%1 of 7 questionsLimited sample
- Companies
- 4questioned at least once
- Reporting periods
- 3with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 4 companies
SHWThe Sherwin-Williams Company3 questions · 3 reporting periods · 1 of 3 challenging
Calendar 2025 Q2
I am trying to understand what gives you confidence on the upper end of the guidance today considering that volumes probably have decreased a little bit
Show response
Heidi cited team discipline, share gains, and new business wins as drivers of PCG confidence; Al noted the Q2 margin decline was ~120bps ex prior-year gain and FX losses.
Calendar 2025 Q1
You mentioned that the contribution from pricing in Q2 will be smaller and the comparable base becomes a bit tougher in Q2. So just trying to understand, where do you expect volume growth to come b...
Show response
Al pointed to res repaint and P&M momentum as volume drivers; commercial and property maintenance expected not to get worse; new res bouncing along.
Calendar 2024 Q4
can you elaborate a little bit on the level of profitability of your market shares gains?
Show response
Al pushed back on the premise, saying new accounts vary by maturity, some come in at competitor price points then move up as they recognize Sherwin's ecosystem value. Heidi added res repaint is the clearest example of trading contractors up.
CFCF Industries2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2025 Q2
Do you see these products as a growing risk to traditional nitrogen producers? Or do you expect farmers to adopt them as a complementary solution?
Show response
Bert expressed skepticism citing inconsistent field results after decades of monitoring. Tony reframed biologicals as yield-enhancement rather than nitrogen replacement, arguing increased yield is worth more to growers than saving a small portion of nitrogen cost.
Calendar 2024 Q4
Does it include potentially Mitsui as well and therefore, you are not going to go ahead with the second plant
Show response
Tony clarified they moved from a smaller 1.2M ton SMR with Mitsui alone to a larger 1.4M ton ATR with both Mitsui and JERA as potential partners.
MOSMosaic Company (The)1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q2
How should we think about the earnings power of this business in a mid-cycle scenario
Show response
Luciano laid out a long-term Fertilizantes EBITDA framework: distribution at $300-500M (13M tons at $30-40/ton), production at $300-350M (4M tons at $75-80/ton), plus coproducts ~$160M annually. Also disclosed China business at ~$30M in H1 with potential to double or triple quickly. Biosciences targeting $250M EBITDA long-term, gated by regulatory approvals.
PPGPPG Industries1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q2
you slightly revised down your organic sales growth guidance for both Architectural Paints and Industrial Coatings
Show response
Knavish explained Architectural downgrade driven by Europe, now assuming current state plus share gains with no market recovery built in. Any stimulus (tariff agreement, Ukraine/Middle East progress) would be upside. Morales called Industrial adjustment 'more rounding in terms of percentages,' related to Q2 China softness.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| SHW The Sherwin-Williams Company | 3 | 33%1 of 3 questions |
| CF CF Industries | 2 | —Rate withheld: fewer than 3 questions |
| MOS Mosaic Company (The) | 1 | —Rate withheld: fewer than 3 questions |
| PPG PPG Industries | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 2 |
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 4 | 25%1 of 4 questions | 4 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q24 questions · challenge rate 25% (1 of 4 questions) · 4 companies
Topics
Topics tagged on this analyst’s questions.
- Margin3
- Revenue Growth3
- Competitive Dynamics2
- Demand2
- Guidance Reliability2
- Capex Investment1
- M&A1